The FDA made two relevant label changes.
The first fraudulent stealth change occurred in 2002 and was detailed in the recent Reuters news article that came out.
- Prior to 2002, the label said “Resolution occurred in all men who discontinued therapy with PROPECIA due to these side effects and in 58% of those who continued therapy”
- After 2002, they changed the label to say “Resolution occurred in men who discontinued therapy with PROPECIA due to these side effects and in most of those who continued therapy.”
The article explains the change in full and then you can click the deposition link to see the interview with the woman who was in charge of managing the label with the FDA. Of course you’ll note that the updated label in no way informs patients of the risks of persistent side effects, but they changed the label in this sneaky way to make it seem as though they were adequately warning the public and FDA.
The second more visible change occurred in April 2012 and was a result of the FDA requiring Merck to change the label. The label began to warn of post marketing reports of persisting sexual dysfunction.
Good luck with things in Latin America. It is less relevant for you, but many other countries began to warn citizens of the risks of their drug before the FDA did. Unless your country uses the FDA label, this probably won’t matter.